Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Altria Group, Inc. (MO) SEC Filings & Earnings Calls

EquiReason read 15 Altria Group, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — Altria extended its $3.0B revolving credit facility by one year to Oct 2030; no new borrowing, no change in terms..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MOAltria Group, Inc.Follow MO — free
Tobacco · Consumer Defensive
—
Price chart with a free account
Market cap
124.1B
P/E TTM
15.6
Dividend yield
5.7%
52-week
—
Next earnings
29 Oct, in 5 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

9 Oct 20268-K · 1.01Altria extended its $3.0B revolving credit facility by one year to Oct 2030; no new borrowing, no change in terms.open

Risks flagged

No material risk identified; routine credit facility extension.

Read the original on SEC EDGAR ↗
28 Aug 20268-K · 5.02, 7.01Altria elects Steven W. Presley to Board of Directors, increasing board size to 11. Presley is CEO of Refresco Benelux, former Nestlé executive.open

Risks flagged

No material risks; routine board appointment

“Standard board election with no disclosed controversies”
Read the original on SEC EDGAR ↗
30 Jul 20268-K · 2.02Net revenues $6.11B (+0% y/y); Revenues net of excise taxes $5.36B (+1% y/y); Reported diluted EPS $1.37 (-3% y/y); Guidance: Adjusted diluted EPS guidance raised to $5.61-$5.72 from prior range.earningsopen

Figures in the filing · each found in the filing text

Net revenues · Q2-2026$6.11B+0% y/y
Revenues net of excise taxes · Q2-2026$5.36B+1% y/y
Reported diluted EPS · Q2-2026$1.37-3% y/y
Adjusted diluted EPS · Q2-2026$1.48+3% y/y
Share repurchases · H1-2026$335M
Dividends paid · H1-2026$3.60B
Adjusted effective tax rate · Q2-202623.0%

Guidance

Adjusted diluted EPS guidance raised to $5.61-$5.72 from prior range.

Altria raised the lower end of its 2026 adjusted EPS guidance, reflecting confidence in smoke-free growth and cost management. Capex guidance also increased for manufacturing consolidation.

Risks flagged

Regulatory and litigation risks remain; NPM adjustment disputes and tobacco litigation ongoing.

“Guidance excludes impact of tobacco and health litigation items and NPM Adjustment Items.”

Macroeconomic uncertainty may pressure adult nicotine consumers.

“Guidance contemplates increased macroeconomic uncertainty facing adult nicotine consumers.”

E-vapor industry growth moderation could impact volumes.

“Guidance contemplates impact of moderated e-vapor industry growth on combustible and e-vapor product volumes.”
Read the original on SEC EDGAR ↗
30 Jul 202610-QAltria reports Q2 2026 results with smokeable segment volume decline offset by pricing, oral segment under pressure.earningsopen

Figures in the filing · each found in the filing text

Domestic cigarettes shipment volume (sticks in millions) · smokeable products · H1-202629,421-3% y/y
Smokeable products segment adjusted OCI margin · smokeable products · H1-202664.9%
Oral tobacco products shipment volume (cans in millions) · oral tobacco products · H1-2026351.6-6% y/y
Oral tobacco products segment adjusted OCI margin · oral tobacco products · H1-202667.0%
Marlboro retail share · smokeable products · H1-202639.6%
Total cigarettes retail share · smokeable products · H1-202645.5%
on! oral nicotine pouch shipment volume (cans in millions) · oral tobacco products · H1-202696.1+5% y/y
on! retail share · oral tobacco products · H1-20268.2%

Risks flagged

FDA regulatory risk

“The FDA's failure to clearly define product pathways and issue marketing orders within the statutory review period has resulted in a market with few authorized smoke-free products available to adult nicotine consumers.” · word for word

Illicit trade risk

“Illicit trade in tobacco products has had, and could continue to have, an adverse impact on our businesses, including the sales volumes and market shares of our operating companies' innovative and smoke-free products and traditional tobacco products.” · word for word

Excise tax risk

“Tax increases are expected to continue to have an adverse impact on sales of our operating companies' products through lower consumption levels and the potential shift in adult nicotine consumer purchases from premium to non-premium or discount cigarettes, to lower-taxed nicotine products or to counterfeit and contraband products.” · word for word

Volume decline risk

“Our smokeable products segment's reported domestic cigarettes shipment volume decreased 2.8%, driven primarily by the industry's decline rate (impacted by the continued discretionary income pressures on adult nicotine consumers)” · word for word
Read the original on SEC EDGAR ↗
27 May 202610-K/A10-K/A is a technical amendment adding ABI financials; no new investment-relevant signals for Altria.SEC ↗
18 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersSEC ↗
30 Apr 202610-QDomestic cigarette shipment volume 13,867 (-2% y/y); Oral tobacco products shipment volume 169.9 (-3% y/y); on! shipment volume 46.2 (+18% y/y)open

Figures in the filing · each found in the filing text

Domestic cigarette shipment volume · Smokeable Products · Q1-202613,867-2% y/y
Oral tobacco products shipment volume · Oral Tobacco Products · Q1-2026169.9-3% y/y
on! shipment volume · Oral Tobacco Products · Q1-202646.2+18% y/y
Reported OCI margin · Smokeable Products · Q1-202665.0%
Adjusted OCI margin · Smokeable Products · Q1-202665.1%
Marlboro retail share · Smokeable Products · Q1-202639.7%
Total cigarettes retail share · Smokeable Products · Q1-202645.4%
Oral tobacco products retail share · Oral Tobacco Products · Q1-202629.0%
on! retail share · Oral Tobacco Products · Q1-20267.8%
Net revenues · Smokeable Products · Q1-2026$4.76B+3% y/y

Risks flagged

FDA regulatory risk

“The FDA's failure to effectively address illicit nicotine products on the market, including illicit disposable e-vapor and oral nicotine pouch products.” · word for word

Excise tax increases

“Tax increases are expected to continue to have an adverse impact on sales of our operating companies' products through lower consumption levels and the potential shift in adult nicotine consumer purchases from premium to non-premium or discount cigarettes.” · word for word

Illicit trade

“Illicit trade in tobacco products has had, and could continue to have, an adverse impact on our businesses, including the sales volumes and market shares of our operating companies' innovative and smoke-free products and traditional tobacco products.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 2.02Q1 2026 adjusted diluted EPS up 7.3% to $1.32; net revenues up 3.2% to $5.4B; reaffirmed FY26 adjusted EPS guidance $5.56-$5.72; strong smokeable segment income growth; $280M share repurchases.earningsopen

Figures in the filing · each found in the filing text

Net revenues · Q1-2026$5.43B+3% y/y
Revenues net of excise taxes · Q1-2026$4.76B+5% y/y
Reported diluted EPS · Q1-2026$1.30
Adjusted diluted EPS · Q1-2026$1.32+7% y/y
Reported effective tax rate · Q1-202623.6%
Adjusted effective tax rate · Q1-202623.1%

Guidance

FY26 adjusted diluted EPS $5.56-$5.72, growth rate 2.5%-5.5% from base of $5.42 in 2025

Reaffirmed full-year adjusted EPS guidance; strong Q1 performance; balanced growth expected between halves.

Risks flagged

NJOY ACE not returning to marketplace in 2026

“that NJOY ACE does not return to the marketplace in 2026” · word for word

Moderated e-vapor industry growth and macroeconomic uncertainty

“Our reaffirmed guidance range now contemplates the impact of moderated e-vapor industry growth on combustible and e-vapor product volumes and increased macroeconomic uncertainty facing adult nicotine consumers.” · word for word
Read the original on SEC EDGAR ↗
2 Apr 2026DEF 14ACEO and CFO succession announced: Sal Mancuso to become CEO and Heather Newman to become CFO, effective after the 2026 Annual Meeting.open

Figures in the filing · each found in the filing text

Adjusted Diluted EPS · FY2025$5.42+4% y/y
Adjusted OCI Margin · FY202562.4%
Dividend Increase · FY20253.9%
Cash Returned to Shareholders · FY2025$8.00B
on! Cumulative Volume (2023-2025) · Oral Tobacco Products · 2023-2025452,400,000
on! U.S. Oral Tobacco Category Share · Oral Tobacco Products · FY20258.2%
Marlboro Share of Premium · Smokeable Products · FY202559.4%
Basic Retail Share (Q4) · Smokeable Products · Q4-20252.1%
Debt-to-Consolidated EBITDA · FY2025$2.00
Adjusted Discretionary Cash Flow · FY2025$9.03B

Guidance

2028 Enterprise Goals: mid-single digits adjusted diluted EPS CAGR from $4.87 base in 2022; progressive dividend growth targeting mid-single digits annually through 2028; total adjusted OCI margin of

2028 Enterprise Goals reaffirmed; strong 2025 performance with adjusted EPS growth, margin expansion, and shareholder returns.

Risks flagged

Illicit e-vapor market disruption

“Due to ongoing market disruption caused by illicit e-vapor products that have evaded the regulatory process, we continue to reassess our smoke-free goals and expect to provide updated goals when we have more clarity on how the legitimate e-vapor market may evolve.” · word for word

ITC exclusion order on NJOY ACE

“the ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States.” · word for word

Regulatory uncertainty for smoke-free products

“We underperformed relative to our expectations. We acquired NJOY in 2023, and our teams made significant progress in the e-vapor category before the ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States.” · word for word
Read the original on SEC EDGAR ↗
25 Feb 202610-KCigarettes shipment volume 61,800,000,000 (-10% y/y); cigars shipment volume 1,800,000,000 (+2% y/y); oral tobacco shipment volume 732,400,000 (-6% y/y)open

Figures in the filing · each found in the filing text

cigarettes shipment volume · smokeable products · FY202561,800,000,000-10% y/y
cigars shipment volume · smokeable products · FY20251,800,000,000+2% y/y
oral tobacco shipment volume · oral tobacco products · FY2025732,400,000-6% y/y
number of employees · 2025-12-315,900
OSHA recordable injury rate · FY20251.7%
female to male salary ratio (unadjusted) · 202598.4%
employees of color to white salary ratio (unadjusted) · 202598.5%
female to male salary ratio (adjusted) · 202599.9%
employees of color to white salary ratio (adjusted) · 202599.9%
percentage of leaf and nicotine suppliers in sustainability programs · 2025100.0%

Risks flagged

Illicit flavored disposable e-vapor products dominate category, undermining FDA-authorized products

“In the e-vapor category, illicit flavored disposable product usage has significantly increased, and such products now comprise the majority of the e-vapor category.” · word for word

ITC bans on NJOY ACE importation and sale in the U.S. remain in effect during appeal

“NJOY ACE , the principal e-vapor product of NJOY, is subject to an exclusion order and cease-and-desist orders issued by the U.S. International Trade Commission (“ITC”) prohibiting the importation and sale of NJOY ACE in the United States, as further discussed in Note 18.” · word for word

Impairments of goodwill and intangible assets in e-vapor reporting unit due to ITC orders and slow enforcement

“In 2025, we recorded impairments of the value of the goodwill and other intangible assets within our e-vapor reporting unit as a result of these orders and our expectation that effective enforcement against illicit flavored disposable e-vapor products would occur more gradually than initially anticipated.” · word for word

Cigarette volume decline accelerating (-10.0% in 2025) driven by consumer shifts and illicit products

“Total smokeable products segment’s cigarettes shipment volume in the United States was 61.8 billion units in 2025, a decrease of 10.0% from 2024.” · word for word

Horizon joint venture has not commercialized any products in the U.S. as of Feb 2026

“As of February 25, 2026, there are no products in the U.S. marketplace from the joint venture.” · word for word
Read the original on SEC EDGAR ↗
29 Jan 20268-K · 2.02, 5.02Net revenues $23.28B (-3% y/y); Revenues net of excise taxes $20.14B (-2% y/y); Adjusted diluted EPS $5.42 (+4% y/y); Guidance: FY2026 adjusted diluted EPS guidance of $5.56-$5.72, representing 2.5%-5.5% growth from FY2025 base of $5.42.earningsopen

Figures in the filing · each found in the filing text

Net revenues · FY2025$23.28B-3% y/y
Revenues net of excise taxes · FY2025$20.14B-2% y/y
Adjusted diluted EPS · FY2025$5.42+4% y/y
Total adjusted OCI margin · FY202562.4%
Share repurchases · FY2025$1.00B
Dividends paid · FY2025$7.00B
Debt-to-Consolidated EBITDA ratio · FY2025$2.00

Guidance

FY2026 adjusted diluted EPS guidance of $5.56-$5.72, representing 2.5%-5.5% growth from FY2025 base of $5.42.

Altria guides FY2026 adjusted diluted EPS growth of 2.5%-5.5%, supported by smoke-free portfolio progress, cost savings, and strong cash returns. Margin remains high with adjusted OCI margin above 60%.

Risks flagged

Illicit e-vapor market disruption continues to pressure smoke-free portfolio goals.

“Due to ongoing market disruption caused by e-vapor products that have evaded the regulatory process (illicit), we continue to reassess our smoke-free goals and expect to provide updated goals when we have more clarity on how the legitimate e-vapor market may evolve.” · word for word
Read the original on SEC EDGAR ↗
29 Jan 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportSEC ↗
11 Dec 20258-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open

Risks flagged

CEO transition risk but mitigated by orderly succession and internal appointment

“CEO retiring in May 2026; successor is current CFO with 30+ years tenure; consulting transition planned”
Read the original on SEC EDGAR ↗
30 Oct 202510-QAltria reported Q3 2025 results with cigarette volume declines but margin expansion, and began commercializing on! PLUS.earningsopen

Figures in the filing · each found in the filing text

Cigarette shipment volume · Smokeable Products · Q3-202546,462-11% y/y
Cigarette shipment volume · Smokeable Products · Q3-202516,192-8% y/y
Marlboro retail share · Smokeable Products · Q3-202540.8%
Marlboro retail share · Smokeable Products · Q3-202540.4%
Smokeable segment adjusted OCI margin · Smokeable Products · Q3-202564.4%
Oral tobacco segment adjusted OCI margin · Oral Tobacco Products · Q3-202569.0%
Oral tobacco net revenue · Oral Tobacco Products · Q3-2025$2.10B+1% y/y
Smokeable segment net revenue · Smokeable Products · Q3-2025$15.37B-4% y/y

Risks flagged

Illicit e-vapor competition

“Our smokeable products segment’s reported domestic cigarettes shipment volume decreased 10.6%, driven primarily by the industry’s decline rate (impacted by the continued growth of flavored disposable e-vapor products, the majority of which we believe have evaded the regulatory process)” · word for word

FDA regulatory uncertainty

“As of October 27, 2025, the FDA has not issued a marketing order with respect to any on! or on! PLUS PMTA.” · word for word

Excise tax increases

“As of October 27, 2025, four states (Hawaii, Indiana, Maine and New Jersey) have increased excise taxes in 2025.” · word for word
Read the original on SEC EDGAR ↗
30 Oct 20258-K · 2.02, 8.01Net revenues $6.07B (-3% y/y); Revenues net of excise taxes $5.25B (-2% y/y); Reported diluted EPS $1.41 (+5% y/y); Guidance: Adjusted EPS guidance raised to $5.37-$5.45 from prior range (implied lower end raised)earningsopen

Figures in the filing · each found in the filing text

Net revenues · Q3-2025$6.07B-3% y/y
Revenues net of excise taxes · Q3-2025$5.25B-2% y/y
Reported diluted EPS · Q3-2025$1.41+5% y/y
Adjusted diluted EPS · Q3-2025$1.45+4% y/y
Depreciation and amortization · FY2025$290M
Dividend per share (annualized) · Q3-2025$4.24+4% y/y
Share repurchases (Q3) · Q3-2025$112M

Guidance

Adjusted EPS guidance raised to $5.37-$5.45 from prior range (implied lower end raised)

Altria raised the lower end of 2025 adjusted EPS guidance, reflecting confidence in earnings growth driven by cost savings and buybacks, while maintaining capex and tax rate outlook.

Risks flagged

Tariff cost pressure on imported inputs; guidance includes estimated impact.

“Our guidance contemplates the current estimated impact of increased tariffs on our costs, based on presently available information.” · word for word

Illicit product enforcement could affect combustible and e-vapor volumes.

“Our guidance assumes limited impact on combustible and e-vapor product volumes from enforcement efforts against products that have evaded the regulatory process (illicit).” · word for word

NJOY ACE not returning to market this year; potential revenue headwind.

“Our guidance assumes ... that NJOY ACE does not return to the marketplace this year.”

Regulatory, litigation, and legislative developments remain dynamic risks.

“We will continue to monitor conditions related to ... regulatory, litigation and legislative developments.” · word for word
Read the original on SEC EDGAR ↗

Altria Group, Inc. — questions

What did Altria Group, Inc. file recently?
15 SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — Altria extended its $3.0B revolving credit facility by one year to Oct 2030; no new borrowing, no change in terms.

Every figure on this page comes from Altria Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.